|
1
|
Esakandari H, Nabi-Afjadi M,
Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM and Bahreini E: A
comprehensive review of COVID-19 characteristics. Biol Proced
Online. 22(19)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui
F, Yee NTS, Liu C, Nerurkar SN, Kai JCY, et al: Epidemiology of
COVID-19: A systematic review and meta-analysis of clinical
characteristics, risk factors, and outcomes. J Med Virol.
93:1449–1458. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kato GJ, Piel FB, Reid CD, Gaston MH,
Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA,
Weatherall DJ, Costa FF and Vichinsky EP: Sickle cell disease. Nat
Rev Dis Primers. 14(18010)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mucalo L, Brandow AM, Dasgupta M, Mason
SF, Simpson PM, Singh A, Taylor BW, Woods KJ, Yusuf FI and
Panepinto JA: Comorbidities are risk factors for hospitalization
and serious COVID-19 illness in children and adults with sickle
cell disease. Blood Adv. 5:2717–2724. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lee JX, Chieng WK, Lau SCD and Tan CE:
COVID-19 and Hemoglobinopathies: A systematic review of clinical
presentations, investigations, and outcomes. Front Med (Lausanne).
8(1848)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Booth C, Inusa B and Obaro SK: Infection
in sickle cell disease: A review. Int J Infect Dis. 14:e2–e12.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hoogenboom WS, Alamuri TT, McMahon DM,
Balanchivadze N, Dabak V, Mitchell WB, Morrone KB, Manwani D and
Duong TQ: Clinical outcomes of COVID-19 in patients with sickle
cell disease and sickle cell trait: A critical appraisal of the
literature. Blood Rev: Nov 20, 2021 (Epub ahead of print).
|
|
8
|
McCormack HM, Horne DJ and Sheather S:
Clinical applications of visual analogue scales: A critical review.
Psychol Med. 18:1007–1019. 1988.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sanyaolu A, Okorie C, Marinkovic A,
Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J and Altaf
M: Comorbidity and its impact on patients with COVID-19. SN Compr
Clin Med. 2:1069–1076. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Alyammahi SK, Abdin SM, Alhamad DW,
Elgendy SM, Altell AT and Omar HA: The dynamic association between
COVID-19 and chronic disorders: An updated insight into prevalence,
mechanisms and therapeutic modalities. Infect Genet Evol.
87(104647)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang B, Li R, Lu Z and Huang Y: Does
comorbidity increase the risk of patients with COVID-19: Evidence
from meta-analysis. Aging (Albany NY). 12:6049–6057.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Minniti CP, Zaidi AU, Nouraie M, Manwani
D, Crouch GD, Crouch AS, Callaghan MU, Carpenter S, Jacobs C, Han
J, et al: Clinical predictors of poor outcomes in patients with
sickle cell disease and COVID-19 infection. Blood Adv. 5:207–215.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Menapace LA and Thein SL: COVID-19 and
sickle cell disease. Haematologica. 105:2501–2504. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ceccarelli M, Marino A, Cosentino F,
Moscatt V, Celesia BM, Gussio M, Bruno R, Rullo EV, Nunnari G and
Cacopardo BS: Post-infectious ST elevation myocardial infarction
following a COVID-19 infection: A case report. Biomed Rep.
16(10)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Marino A, Pampaloni A, Scuderi D,
Cosentino F, Moscatt V, Ceccarelli M, Gussio M, Celesia BM, Bruno
R, Borraccino S, et al: High-flow nasal cannula oxygenation and
tocilizumab administration in patients critically ill with
COVID-19: A report of three cases and a literature review. World
Acad Sci J. 2(23)2020.
|
|
16
|
Cannas G, Merazga S and Virot E: Sickle
cell disease and infections in high- and low-income countries.
Mediterr J Hematol Infect Dis. 11(e2019042)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Strouse JJ, Reller ME, Bundy DG, Amoako M,
Cancio M, Han RN, Valsamakis A and Casella JF: Severe pandemic H1N1
and seasonal influenza in children and young adults with sickle
cell disease. Blood. 116:3431–3434. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chakravorty S, Padmore-Payne G, Ike F,
Tshibangu V, Graham C, Rees D and Stuart-Smith S: COVID-19 in
patients with sickle cell disease-A case series from a UK tertiary
hospital. Haematologica. 105:2691–2693. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Brandow AM, Carroll CP, Creary S,
Edwards-Elliott R, Glassberg J, Hurley RW, Kutlar A, Seisa M,
Stinson J, Strouse JJ, et al: American society of hematology 2020
guidelines for sickle cell disease: Management of acute and chronic
pain. Blood Adv. 4:2656–2701. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Russo G, De Franceschi L, Colombatti R,
Rigano P, Perrotta S, Voi V, Palazzi G, Fidone C, Quota A,
Graziadei G, et al: Current challenges in the management of
patients with sickle cell disease-A report of the Italian
experience. Orphanet J Rare Dis. 14(120)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
El-Sokkary R, Uysal S, Erdem H, Kullar R,
Pekok AU, Amer F, Grgić S, Carevic B, El-Kholy A, Liskova A, et al:
Profiles of multidrug-resistant organisms among patients with
bacteremia in intensive care units: An international ID-IRI survey.
Eur J Clin Microbiol Infect Dis. 40:2323–2334. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Erdem H, Hargreaves S, Ankarali H,
Caskurlu H, Ceviker SA, Bahar-Kacmaz A, Meric-Koc M, Altindis M,
Yildiz-Kirazaldi Y, Kizilates F, et al: Managing adult patients
with infectious diseases in emergency departments: International
ID-IRI study. J Chemother. 33:302–318. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Marino A, Zafarana G, Ceccarelli M,
Cosentino F, Moscatt V, Bruno G, Bruno R, Benanti F, Cacopardo B
and Celesia BM: Immunological and clinical impact of DAA-Mediated
HCV Eradication in a Cohort of HIV/HCV Coinfected Patients:
Monocentric Italian Experience. Diagnostics (Basel).
11(2336)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Celesia BM, Marino A, Borracino S,
Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo
B and Panarello G: Successful extracorporeal membrane oxygenation
treatment in an acquired immune deficiency syndrome (AIDS) patient
with acute respiratory distress syndrome (ARDS) complicating
pneumocystis jirovecii pneumonia: A challenging case. Am J Case
Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ceccarelli M, Venanzi Rullo E, Marino MA,
D'Aleo F, Pellicanò GF, D'Andrea F, Marino A, Cacopardo B, Celesia
BM, La Rocca G, et al: Non-AIDS defining cancers: A comprehensive
update on diagnosis and management. Eur Rev Med Pharmacol Sci.
24:3849–3875. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Celesia BM, Marino A, Del Vecchio RF,
Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it safe
and cost saving to defer the CD4+ cell count monitoring in stable
patients on art with more than 350 or 500 cells/µl? Mediterr J
Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Marino A, Cosentino F, Ceccarelli M,
Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G,
Benanti F, et al: Entecavir resistance in a patient with
treatment-naïve HBV: A case report. Mol Clin Oncol.
14(113)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
McGann PT and Ware RE: Hydroxyurea therapy
for sickle cell anemia. Expert Opin Drug Saf. 14:1749–1758.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yasara N, Premawardhena A and Mettananda
S: A comprehensive review of hydroxyurea for β-haemoglobinopathies:
The role revisited during COVID-19 pandemic Orphanet J Rare. Dis.
16(114)2021.PubMed/NCBI View Article : Google Scholar
|
